Loading...
XNASLEXX
Market cap37mUSD
Dec 24, Last price  
2.16USD
1D
-1.79%
1Q
-30.75%
Jan 2017
-76.77%
IPO
-59.99%
Name

Lexaria Bioscience Corp

Chart & Performance

D1W1MN
XNAS:LEXX chart
P/E
P/S
81.22
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
36.71%
Rev. gr., 5y
15.84%
Revenues
464k
+105.24%
20,30720,307253,148900,789421,955362,4711,133,7661,357,7621,097,45514,70240,71863,639433,287222,610384,543722,738255,397226,208464,278
Net income
-6m
L-13.05%
-75,722-508,257-1,055,888-978,490-753,573-552,462-538,226-251,508-1,871,209-1,770,500-1,214,773-1,869,277-6,598,843-4,198,036-4,030,327-2,504,302-7,269,324-6,664,899-5,795,345
CFO
-5m
L-15.68%
-42,322-153,375-218,56229,035-36,402-330,336-195,103135,943321,000-1,501,027-660,856-1,545,909-2,517,979-3,005,555-2,663,281-3,989,678-4,879,339-5,881,237-4,959,003
Earnings
Apr 07, 2025

Profile

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
IPO date
Oct 28, 2009
Employees
7
Domiciled in
CA
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑082023‑082022‑082021‑082020‑082019‑082018‑082017‑082016‑082015‑08
Income
Revenues
464
105.24%
226
-11.43%
255
-64.66%
Cost of revenue
6,217
6,760
7,639
Unusual Expense (Income)
NOPBT
(5,753)
(6,534)
(7,384)
NOPBT Margin
Operating Taxes
(114)
Tax Rate
NOPAT
(5,753)
(6,534)
(7,269)
Net income
(5,795)
-13.05%
(6,665)
-8.31%
(7,269)
190.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,209
1,590
BB yield
-8.69%
-22.89%
Debt
Debt current
28
28
43
Long-term debt
247
300
57
Deferred revenue
Other long-term liabilities
Net debt
(6,281)
(1,150)
(6,061)
Cash flow
Cash from operating activities
(4,959)
(5,881)
(4,879)
CAPEX
(34)
(131)
Cash from investing activities
(189)
(170)
(181)
Cash from financing activities
10,315
1,590
(45)
FCF
(5,504)
(6,419)
(7,258)
Balance
Cash
6,556
1,478
6,161
Long term investments
Excess cash
6,532
1,466
6,148
Stockholders' equity
(51,956)
(46,119)
(39,409)
Invested Capital
59,752
48,963
47,060
ROIC
ROCE
EV
Common stock shares outstanding
12,384
6,614
5,885
Price
3.91
272.42%
1.05
-64.53%
2.96
-52.41%
Market cap
48,421
597.30%
6,944
-60.14%
17,420
-36.22%
EV
41,763
5,430
11,043
EBITDA
(5,677)
(6,389)
(7,242)
EV/EBITDA
Interest
Interest/NOPBT